-
Featured
Building a Robot to Assist Individuals with Upper-Limb Disabilities
A team of investigators from Massachusetts General Hospital and Harvard University are co-authors of a paper that details a major update to the software powering an inflatable, wearable shoulder robot. The device is designed to provide personalized movement assistance for people with upper-limb impairment, such as ALS or stroke patients.
-
Lifetime Achievement Award Recognizes Catalyst of ALS Therapy Research and Development
The American Academy of Neurology recognizes the career achievements and global impact of Merit Cudkowicz, MD, MSc, for advancing ALS research and treatment.
-
Innovative Platform Trial Reshapes the Future of ALS Drug Discovery and Evaluation
Researchers at Massachusetts General Hospital and collaborators publish results of the first four drug candidates evaluated using the HEALEY ALS Platform Trial.
-
Antisense Drugs Mimic TDP-43 Function, Might Treat ALS and Some Dementias
Clotilde Lagier-Tourenne, MD, PhD, and colleagues have demonstrated in vitro and in vivo efficacy of antisense oligonucleotides in preventing missplicing of stathmin-2 in a mouse model of amyotrophic lateral sclerosis attributable to deficiency of the protein TDP-43.
-
Design and Statistical Innovations in the Healey ALS Platform Trial
Sabrina Paganoni, MD, PhD, Eric A. Macklin, PhD, and colleagues explain the statistical approaches used in the Healey ALS Platform Trial to integrate functional and survival outcomes and account for potential differences in the outcomes of participants within the shared control group.
-
Genomic Therapeutics in Action: Antisense Oligonucleotides Interventions Reverses Neurodegeneration
Physician-investigators at Massachusetts General Hospital recently published findings that provide a critical step forward in understanding the mechanisms underlying a host of neurodegenerative diseases.
ALS Contributors
-
Clotilde Lagier-Tourenne, MD, PhD
Associate Professor of Neurology, Massachusetts General Hospital and Harvard Medical School
Recent Article
Antisense Drugs Mimic TDP-43 Function, Might Treat ALS and Some Dementias
-
Ghazaleh Sadri-Vakili, MS, PhD
Assistant in Neuroscience, Massachusetts General Hospital, Assistant Professor of Neurology, Harvard Medical School
Recent Article
Novel Target Identified for Treatment of ALS
-
James D. Berry, MD, MPH
Co-director, Multidisciplinary Amyotrophic Lateral Sclerosis (ALS) Clinic
Recent Article
Healey Platform ALS Trial Expected to Expedite U.S. Approval of New Treatments
-
Merit Ester Cudkowicz, MD, MSc
Chief, Neurology Service, Director of the Sean M. Healey & AMG Center for ALS at Mass General, Director of Neurological Clinical Research Institute and the Jilieane Dorn Professor of Neurology, Harvard Medical School
Recent Article
Lifetime Achievement Award Recognizes Catalyst of ALS Therapy Research and Development
-
Nazem Atassi, MD
Associate Director, Neurological Clinical Research Institute (NCRI), Mass General Hospital, Associate Professor of Neurology, Harvard Medical School
Recent Article
High-Dose Tamoxifen "Wins" Selection Trial in ALS
Neuroscience Care at Mass General
Through a combination of unmatched expertise, creativity and compassion, Mass General Neuroscience relentlessly advances the fields of Neurosurgery, Neurology and Psychiatry to unleash our patients’ potential.